AKT1 and colorectal carcinoma: Our results suggest that in addition to inhibiting AKT phosphorylation at Ser473, targeting cPLA2α by siRNA or inhibitor can also retard cell-cycle progression and inhibit cell proliferation in CRC cells harbouring PI3K mutations.